{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-105706","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2024-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.775355+00:00","generated_at":"2026-05-31T05:12:08.870204+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Precision BioSciences names Murray Abramson SVP Clinical Development, John Fry as HBV Advisor; CMO List retires","bullets":["Alan List, CMO, retiring effective Sept 13, 2024; will transition to clinical consultant at $325/hour and remain on SAB.","Murray Abramson, MD MPH, appointed SVP Head of Clinical Development; previously SVP at Tempus, VP at Biogen, roles at Merck.","John Fry appointed Strategic Clinical Advisor for hepatitis; former EVP at Aligos Therapeutics, Head Early Development at Alios.","Leadership changes strengthen team for PBGENE-HBV (hepatitis B) with anticipated Phase 1 data milestones in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-105706","json":"https://secwatch.observer/filing/0000950170-24-105706.json","markdown":"https://secwatch.observer/filing/0000950170-24-105706.md","text":"https://secwatch.observer/filing/0000950170-24-105706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000095017024105706/0000950170-24-105706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000095017024105706/dtil-20240909.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:12:08.870204+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f2dae946dc","claim":"Alan List departed as Chief Medical Officer at PRECISION BIOSCIENCES INC.","evidence_excerpt":"On September 9, 2024, Alan List, M.D., the Company’s Chief Medical Officer, notified Precision BioSciences, Inc. (the “Company”) that he will be retiring from the Company, effective September 13, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357874/000095017024105706/0000950170-24-105706-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"will be retiring"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}